BRPI1005951A2 - polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5 - Google Patents
polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5Info
- Publication number
- BRPI1005951A2 BRPI1005951A2 BRPI1005951A BRPI1005951A BRPI1005951A2 BR PI1005951 A2 BRPI1005951 A2 BR PI1005951A2 BR PI1005951 A BRPI1005951 A BR PI1005951A BR PI1005951 A BRPI1005951 A BR PI1005951A BR PI1005951 A2 BRPI1005951 A2 BR PI1005951A2
- Authority
- BR
- Brazil
- Prior art keywords
- long
- pten
- individual
- solid tumor
- phosphatase polypeptide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title 5
- 229920001184 polypeptide Polymers 0.000 title 5
- 108090000765 processed proteins & peptides Proteins 0.000 title 5
- 102000004196 processed proteins & peptides Human genes 0.000 title 5
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 title 3
- 102000008068 Tensins Human genes 0.000 title 3
- 108010088950 Tensins Proteins 0.000 title 3
- 210000004027 cell Anatomy 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 2
- 102000039446 nucleic acids Human genes 0.000 title 2
- 108020004707 nucleic acids Proteins 0.000 title 2
- 150000007523 nucleic acids Chemical class 0.000 title 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 102000007079 Peptide Fragments Human genes 0.000 title 1
- 108010033276 Peptide Fragments Proteins 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 210000004204 blood vessel Anatomy 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000005167 vascular cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20797409P | 2009-02-17 | 2009-02-17 | |
| PCT/US2010/000469 WO2010096173A2 (en) | 2009-02-17 | 2010-02-17 | Identification of extracellular form of pten that can be used to treat tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1005951A2 true BRPI1005951A2 (pt) | 2016-10-11 |
Family
ID=42634379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1005951A BRPI1005951A2 (pt) | 2009-02-17 | 2010-02-17 | polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9017981B2 (pt) |
| EP (1) | EP2400973B1 (pt) |
| JP (2) | JP5767117B2 (pt) |
| CN (1) | CN102387810B (pt) |
| AU (2) | AU2010216370A1 (pt) |
| BR (1) | BRPI1005951A2 (pt) |
| CA (1) | CA2752590C (pt) |
| CY (1) | CY1118861T1 (pt) |
| DK (1) | DK2400973T3 (pt) |
| ES (1) | ES2623393T3 (pt) |
| HR (1) | HRP20170306T1 (pt) |
| HU (1) | HUE032028T2 (pt) |
| LT (1) | LT2400973T (pt) |
| MX (1) | MX2011008695A (pt) |
| PL (1) | PL2400973T3 (pt) |
| PT (1) | PT2400973T (pt) |
| SI (1) | SI2400973T1 (pt) |
| SM (1) | SMT201700159T1 (pt) |
| WO (1) | WO2010096173A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011218037B2 (en) | 2010-02-17 | 2016-10-13 | The Trustees Of Columbia University In The City Of New York | Use of PTEN-long leader sequence for transmembrane delivery of molecules |
| WO2015105957A1 (en) | 2014-01-08 | 2015-07-16 | Shriners Hospitals For Children | Pten antagonist peptides and methods of using the same |
| KR102780496B1 (ko) * | 2016-07-29 | 2025-03-11 | 오하이오 스테이트 이노베이션 파운데이션 | 종양용해성 바이러스에 의한 PTEN-Long의 발현 |
| CN109022461B (zh) | 2017-06-08 | 2022-01-14 | 中山大学附属第一医院 | 一种PTEN基因的上游开放阅读框45aa-uORF核苷酸序列及其编码的多肽的应用 |
| CN108504671A (zh) * | 2018-03-28 | 2018-09-07 | 宁波市医疗中心李惠利医院 | 一种PTEN-Long蛋白纯化制备方法 |
| IL314908A (en) | 2018-03-29 | 2024-10-01 | Technion Res & Dev Foundation | Vesicles comprising a pten inhibitor and uses of same |
| WO2020208609A1 (en) * | 2019-04-12 | 2020-10-15 | Therapten Biosciences Inc. | Compositions and methods to manufacture phosphatase and tensin homolog (pten) fusions |
| CN114423860A (zh) * | 2019-08-05 | 2022-04-29 | 迈索布拉斯特国际有限公司 | 包含病毒载体的细胞组合物及治疗方法 |
| CN112813046A (zh) * | 2021-01-08 | 2021-05-18 | 北京大学 | 一种pten亚型蛋白及其应用 |
| CN112877309B (zh) * | 2021-02-19 | 2022-05-17 | 北京大学 | 一种N端延长型PTEN亚型PTENζ蛋白及其编码基因和应用 |
| WO2024163335A2 (en) * | 2023-01-30 | 2024-08-08 | The Board Of Regents Of The University Of Texas System | Pten gene therapy vectors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482795B1 (en) * | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
| AU6513701A (en) | 2000-05-30 | 2001-12-11 | Advanced Res & Tech Inst | Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways |
| US20040266713A1 (en) | 2003-04-23 | 2004-12-30 | Shan Lu | Methods and compositions for solid tumor treatment |
| CA2581423A1 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2011218037B2 (en) | 2010-02-17 | 2016-10-13 | The Trustees Of Columbia University In The City Of New York | Use of PTEN-long leader sequence for transmembrane delivery of molecules |
-
2010
- 2010-02-17 BR BRPI1005951A patent/BRPI1005951A2/pt not_active Application Discontinuation
- 2010-02-17 HR HRP20170306TT patent/HRP20170306T1/hr unknown
- 2010-02-17 HU HUE10744058A patent/HUE032028T2/en unknown
- 2010-02-17 EP EP10744058.8A patent/EP2400973B1/en active Active
- 2010-02-17 CN CN201080016333.3A patent/CN102387810B/zh not_active Expired - Fee Related
- 2010-02-17 MX MX2011008695A patent/MX2011008695A/es active IP Right Grant
- 2010-02-17 SM SM20170159T patent/SMT201700159T1/it unknown
- 2010-02-17 US US13/201,969 patent/US9017981B2/en not_active Expired - Fee Related
- 2010-02-17 PT PT107440588T patent/PT2400973T/pt unknown
- 2010-02-17 WO PCT/US2010/000469 patent/WO2010096173A2/en not_active Ceased
- 2010-02-17 PL PL10744058T patent/PL2400973T3/pl unknown
- 2010-02-17 LT LTEP10744058.8T patent/LT2400973T/lt unknown
- 2010-02-17 CA CA2752590A patent/CA2752590C/en not_active Expired - Fee Related
- 2010-02-17 SI SI201031412A patent/SI2400973T1/sl unknown
- 2010-02-17 ES ES10744058.8T patent/ES2623393T3/es active Active
- 2010-02-17 JP JP2011551062A patent/JP5767117B2/ja not_active Expired - Fee Related
- 2010-02-17 DK DK10744058.8T patent/DK2400973T3/en active
- 2010-02-17 AU AU2010216370A patent/AU2010216370A1/en not_active Abandoned
-
2015
- 2015-06-18 JP JP2015123092A patent/JP5973035B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-21 AU AU2016231517A patent/AU2016231517B2/en not_active Ceased
-
2017
- 2017-02-28 CY CY20171100268T patent/CY1118861T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2400973B1 (en) | 2016-11-30 |
| CN102387810A (zh) | 2012-03-21 |
| DK2400973T3 (en) | 2017-03-06 |
| US20120039861A1 (en) | 2012-02-16 |
| US9017981B2 (en) | 2015-04-28 |
| PT2400973T (pt) | 2017-03-07 |
| HRP20170306T1 (hr) | 2017-04-21 |
| AU2016231517B2 (en) | 2018-01-25 |
| JP2012517827A (ja) | 2012-08-09 |
| MX2011008695A (es) | 2011-10-14 |
| EP2400973A2 (en) | 2012-01-04 |
| LT2400973T (lt) | 2017-04-10 |
| EP2400973A4 (en) | 2013-02-27 |
| HUE032028T2 (en) | 2017-08-28 |
| CA2752590C (en) | 2017-08-22 |
| WO2010096173A2 (en) | 2010-08-26 |
| AU2016231517A1 (en) | 2016-10-06 |
| PL2400973T3 (pl) | 2017-09-29 |
| CY1118861T1 (el) | 2018-01-10 |
| CA2752590A1 (en) | 2010-08-26 |
| WO2010096173A3 (en) | 2010-10-21 |
| CN102387810B (zh) | 2017-08-04 |
| JP2015231372A (ja) | 2015-12-24 |
| ES2623393T3 (es) | 2017-07-11 |
| AU2010216370A1 (en) | 2011-09-22 |
| SI2400973T1 (sl) | 2017-05-31 |
| JP5767117B2 (ja) | 2015-08-19 |
| SMT201700159T1 (it) | 2017-05-08 |
| JP5973035B2 (ja) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05670A (pt) | ||
| Mungunsukh et al. | Hepatocyte growth factor isoforms in tissue repair, cancer, and fibrotic remodeling | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| SG10201907775QA (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen | |
| MX2012002216A (es) | Nueva endolisina obpgplys. | |
| UY31875A (es) | Novedosos genes involucrados en la biosíntesis | |
| BR112014001978B8 (pt) | Molécula de ácido nucleico recombinante, célula hospedeira, polipeptídeo, composição, métodos para controle, para proteção e para exterminação de uma população de pragas de lepidópteros ou coleópteros, método para produção de um polipeptídeo com atividade pesticida e método para aumentar a produtividade de uma planta | |
| BR112014026162A2 (pt) | Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma | |
| BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
| Lü et al. | Characterization and expression analysis of Paralichthys olivaceus voltage-dependent anion channel (VDAC) gene in response to virus infection | |
| JP6025002B2 (ja) | 骨形成または血管新生促進用ペプチドbfp4およびその用途 | |
| WO2010096173A3 (en) | Identification of extracellular form of pten that can be used to treat tumors | |
| Sadeghi-Ardebili et al. | Functional characterization of the dimeric form of PDGF-derived fusion peptide fabricated based on theoretical arguments | |
| BR112013025665B8 (pt) | Molécula de ácido nucleico recombinante, vetor, microrganismo transgênico, polipeptídeo recombinante e seu método de produção, composição, métodos para controlar ou exterminar uma população de pragas, para proteger uma planta de uma praga, e para aumentar o rendimento em uma planta | |
| Yang et al. | High-efficiency production of bioactive oleosin-basic fibroblast growth factor in A. thaliana and evaluation of wound healing | |
| Kindrachuk et al. | Structure-activity relationships of multifunctional host defence peptides | |
| WO2010011994A3 (en) | Polypeptides and uses thereof | |
| Nakayama et al. | Structural stability of human fibroblast growth factor-1 is essential for protective effects against radiation-induced intestinal damage | |
| Xue et al. | Construction, expression, and characterization of thymosin alpha 1 tandem repeats in Escherichia coli | |
| Jeyaseelan et al. | Structurally conserved α-neurotoxin genes encode functionally diverse proteins in the venom of Naja sputatrix | |
| CN101891824A (zh) | 一种血管靶向可溶性融合蛋白TrxHis-hDll1-RGD | |
| EP3536790A1 (en) | Vector for expressing human epidermal growth factor or skin-permeable human epidermal growth factor, and microalgae transformed with vector | |
| Shu-Shan et al. | Comparative proteomic analysis of hearts of adult SCNT Bama miniature pigs (Sus scrofa) | |
| CN103724415A (zh) | 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用 | |
| Chan et al. | Secretome analysis of skeletal myogenesis using SILAC and shotgun proteomics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |